Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of disitamab vedotin plus ADT in metastatic castration-resistant prostate cancer after standard treatment failure
ChiCTR2400085539Phase 2Not yet recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Jiangxi Cancer Hospital. Primary endpoint: PSA response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2400085539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085539.